• Most Popular
  • Most Shared

EU panel recommends Alimta use for lung cancer

Fri Feb 22, 2008 9:53am EST

Stocks

   

NEW YORK, Feb 22 (Reuters) - Eli Lilly and Co (LLY.N) on Friday said an advisory panel to European regulators has recommended that its Alimta drug be approved for the new use as a first-line treatment for advanced lung cancer.

Stocks

The Indianapolis drugmaker said the favorable opinion from the Committee for Medicinal Products will likely sway the European Medicines Agency to formally approve the new use of Alimta within a few months.

Alimta, currently approved to treat cancer caused by exposure to asbestos and second-line treatment of lung cancer, is one of Lilly's fastest growing products. It is likewise awaiting approval in the United States for first-line use against advanced non-small cell lung cancer -- the most common form of the hard-to-treat cancer. (Reporting by Ransdell Pierson, editing by Gerald E. McCormick)

Stocks


More from Reuters

Photo

AIG executive resigns over pay limits

NEW YORK (Reuters) - A top executive at American International Group Inc has resigned because of pay curbs imposed by the Obama Administration's pay czar, the insurer said on Wednesday.

» More Top News
A security camera sits on a building in New York City March 6, 2008. REUTERS/Joshua Lott

Trial run in Times Square

Critics say the Sept. 11 trials will endanger America's most populated city. Will a New Year's Eve plan hold up as New York's security template?  Full Article 

U.S.
People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid
Rolfe Winkler:

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article 

    Commentary